Current prospective research trials using hydroxyurea therapy for SCA in sub-Saharan Africa
| Clinical trial . | ClinicalTrials.gov and status . | Performance sites . | No. of participants . | Study end points . |
|---|---|---|---|---|
| Sickle Cell Disease–Stroke Prevention in Nigeria Trial (SPIN) | NCT01801423 | Kano, Nigeria | 40 | TCD velocity |
| Active, not recruiting | ||||
| Realizing Effectiveness of Hydroxyurea Across Continents (REACH) | NCT01966731 | Luanda, Angola; Kinshasa, DRC; Kilifi, Kenya; Mbale Uganda | 600 | Adherence, toxicity, dosing |
| Recruiting | ||||
| Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM) | NCT01976416 | Kampala, Uganda | 200 | Malaria events |
| Active, not recruiting | ||||
| Risk Clinical Stratification of Sickle Cell Disease in Nigeria: Assessment of Efficacy/Safety of Hydroxyurea Treatment | NCT02149537 | Ibadan, Nigeria | 40 | Cytopenia |
| Enrolling by invitation | ||||
| Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II (SPRING) | NCT02560935 | Kano, Nigeria | 440 | Stroke occurrence |
| Recruiting | ||||
| Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa (SPRINT) | NCT02675790 | Kano, Nigeria | 60 | Stroke recurrence |
| Not yet recruiting |
| Clinical trial . | ClinicalTrials.gov and status . | Performance sites . | No. of participants . | Study end points . |
|---|---|---|---|---|
| Sickle Cell Disease–Stroke Prevention in Nigeria Trial (SPIN) | NCT01801423 | Kano, Nigeria | 40 | TCD velocity |
| Active, not recruiting | ||||
| Realizing Effectiveness of Hydroxyurea Across Continents (REACH) | NCT01966731 | Luanda, Angola; Kinshasa, DRC; Kilifi, Kenya; Mbale Uganda | 600 | Adherence, toxicity, dosing |
| Recruiting | ||||
| Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM) | NCT01976416 | Kampala, Uganda | 200 | Malaria events |
| Active, not recruiting | ||||
| Risk Clinical Stratification of Sickle Cell Disease in Nigeria: Assessment of Efficacy/Safety of Hydroxyurea Treatment | NCT02149537 | Ibadan, Nigeria | 40 | Cytopenia |
| Enrolling by invitation | ||||
| Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II (SPRING) | NCT02560935 | Kano, Nigeria | 440 | Stroke occurrence |
| Recruiting | ||||
| Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa (SPRINT) | NCT02675790 | Kano, Nigeria | 60 | Stroke recurrence |
| Not yet recruiting |
The ClinicalTrials.gov Web site was last accessed September 29, 2016.